Recombinant Technologies LLC is an emerging biotechnology company based in Cheshire, CT, focused on developing innovative therapeutics for neurodegenerative diseases, with a particular emphasis on Alzheimer's disease. With their flagship therapeutic, AmyTrap-3, the company aims to address the unmet medical need of effectively and safely treating beta-amyloidopathy disease patients, while also envisioning their technology making a significant clinical impact on other neurodegenerative diseases.
Recombinant Technologies' mission is to improve the quality of life for patients by bringing their proof-of-concept tested and pre-clinically validated beta-amyloid capturing molecules into the clinic, effectively alleviating beta-amyloidopathy symptoms without subjecting patients to pain and suffering. With a strong focus on research and development, the company has invested over $2M in the development of the AmyTrap molecule and the AmyTrapper plasma-filtration column, aiming to provide a game-changing treatment for Alzheimer's disease and other related conditions.
Generated from the website